Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations [ID3751]

  • Discontinued
  • GID-TA10616
Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.